BioVie, Inc. (BIVI)
2.08
-0.06
(-2.80%)
USD |
NASDAQ |
Aug 25, 16:00
2.055
-0.02
(-1.20%)
After-Hours: 19:59
BioVie Enterprise Value : 7.439M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 7.439M |
| August 21, 2026 | 6.006M |
| August 20, 2026 | 5.327M |
| August 19, 2026 | 1.405M |
| August 18, 2026 | -1.428M |
| August 17, 2026 | 0.1228M |
| August 14, 2026 | 1.858M |
| August 13, 2026 | 3.064M |
| August 12, 2026 | 3.064M |
| August 11, 2026 | 0.8771M |
| August 10, 2026 | -0.4051M |
| August 07, 2026 | -1.165M |
| August 06, 2026 | 1.480M |
| August 05, 2026 | 6.685M |
| August 04, 2026 | 5.101M |
| August 03, 2026 | 3.517M |
| July 31, 2026 | 2.763M |
| July 30, 2026 | 2.084M |
| July 29, 2026 | 0.8017M |
| July 28, 2026 | 1.330M |
| July 27, 2026 | 1.631M |
| July 24, 2026 | 1.631M |
| July 23, 2026 | 2.159M |
| July 22, 2026 | 1.405M |
| July 21, 2026 | 1.028M |
| Date | Value |
|---|---|
| July 20, 2026 | 2.046M |
| July 17, 2026 | 4.875M |
| July 16, 2026 | 4.271M |
| July 15, 2026 | 4.648M |
| July 14, 2026 | 3.215M |
| July 13, 2026 | 3.668M |
| July 10, 2026 | 8.420M |
| July 09, 2026 | 8.193M |
| July 08, 2026 | 7.741M |
| July 07, 2026 | 7.59M |
| July 06, 2026 | 7.138M |
| July 02, 2026 | 6.006M |
| July 01, 2026 | 7.741M |
| June 30, 2026 | 5.931M |
| June 29, 2026 | 2.356M |
| June 26, 2026 | 1.828M |
| June 25, 2026 | 0.6211M |
| June 24, 2026 | 1.677M |
| June 23, 2026 | 1.828M |
| June 22, 2026 | 1.828M |
| June 18, 2026 | 0.4703M |
| June 17, 2026 | 0.6965M |
| June 16, 2026 | 0.6211M |
| June 15, 2026 | -0.2839M |
| June 12, 2026 | -0.5102M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 283.25B |
| Anika Therapeutics, Inc. | 272.43M |
| BioCryst Pharmaceuticals, Inc. | 2.955B |
| Imunon, Inc. | 8.399M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.646M |
| Total Expenses (Quarterly) | 5.646M |
| EPS Diluted (Quarterly) | -0.7485 |
| Earnings Yield | -153.7% |
| Normalized Earnings Yield | -153.72 |